Sphera Funds Management’s Aprea Therapeutics APRE Stock Holding History

Sphera Funds Management’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$206K	Hold	270,000	–	–	0.03%	95
2025 Q4	$230K	Hold	270,000	–	–	0.04%	95
2025 Q3	$398K	Hold	270,000	–	–	0.08%	108
2025 Q2	$456K	Hold	270,000	–	–	0.11%	100
2025 Q1	$551K	Hold	270,000	–	–	0.13%	102
2024 Q4	$888K	Hold	270,000	–	–	0.16%	95
2024 Q3	$743K	Hold	270,000	–	–	0.12%	102
2024 Q2	$1.1M	Hold	270,000	–	–	0.15%	104
2024 Q1	$1.81M	Buy	+270,000	New	+$1.68M	0.25%	81
2020 Q3	–	Sell	-7,914	Closed	-$6.14M	–	98
2020 Q2	$6.14M	Buy	+7,914	New	+$5.19M	0.58%	44

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Sphera Funds Management's APRE Position: Q1 2026 in Review

Sphera Funds Management held its Aprea Therapeutics (APRE) position steady in Q1 2026 at 270,000 shares worth $206K. The position accounts for 0.03% of the portfolio, ranked #95.

Sphera Funds Management first reported a position in APRE in Q2 2020 and has held it in 10 quarters since. The position peaked at $6.14M in Q2 2020. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

Sphera Funds Management held 270,000 shares of Aprea Therapeutics worth $206K as of Q1 2026.
Sphera Funds Management left its Aprea Therapeutics share count unchanged in Q1 2026.
Aprea Therapeutics made up 0.03% of Sphera Funds Management's portfolio in Q1 2026, its #95 holding.
Sphera Funds Management first reported a position in Aprea Therapeutics in Q2 2020 and has held it in 10 quarters since.
Sphera Funds Management's Aprea Therapeutics position peaked at $6.14M in Q2 2020.
22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.